drugset / Trial / NCT01462929

Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01462929

Phase 3 Completed 414 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of the present study is to evaluate the 24h bronchodilatory efficacy of inhaled aclidinium bromide 400 µg administered twice a day versus placebo and tiotropium bromide, respectively, after 6 weeks of treatment.

Timeline

Start
2011-11
Primary completion
2012-03
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclidinium Small molecule 400 ug Inhaled
Comparator Tiotropium Other / unclassified 18 ug Inhaled